Actionable news
All posts from Actionable news
Actionable news in ADMA: ADMA BIOLOGICS Inc,

ADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application

RAMSEY, N.J., July 29, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for RI-002, an Intravenous Immune Globulin (IVIG), for the treatment of patients with Primary Humoral Immunodeficiency Disease (PIDD).

The CRL did not cite any concerns with the clinical safety and efficacy data for RI-002 submitted by ADMA in the BLA, nor has the FDA requested any additional clinical studies be conducted prior to FDA approval of RI-002 for PIDD.

The FDA identified in the CRL certain outstanding inspection issues and deficiencies at ADMA’s third-party contract manufacturers, including its contract drug substance and product manufacturer, its contract fill and finisher and compliance issues with a third-party contract testing laboratory, and requested documentation of corrections for a number of those issues.

ADMA has been informed by its third party drug substance and product manufacturer that it is working to resolve the outstanding inspection issues. ADMA will work diligently with the Company’s third party drug substance and product manufacturer, its contract fill and finish provider and a third-party contract testing laboratory to monitor their efforts in addressing and resolving outstanding issues relating to the observations. The Company will work with the agency to reach an agreement on acceptable language for the package insert and container and vial labeling, if and when approval is granted.

“ADMA is highly committed to bring...